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A B S T R A C T
Background and aims: Previously, colorectal cancer (CRC) metastasis of both liver and lungs was considered
disseminated disease, which contraindicated surgical metastasectomies. Increasing evidence from studies on
patient series have indicated that survival improved after resecting both liver and lung metastases. However,
those results and long-term outcomes remain controversial. We aimed to compare surgical outcomes between
patients treated for both liver and lung metastases to the patients who had only isolated liver or lung metastases.
Material and methods: All patients (n= 105) underwent surgery for CRC metastases between July 2002 and
September 2015. Three groups were compared: the sequentially operated group (n= 33 patients) underwent
sequential liver and lung resections; the liver group (n= 38 patients) underwent liver resections; and the lung
group (n= 34 patients) underwent lung resections. The main endpoints were long-term survival rates.
Results: The groups were not different in disease-free survival (P=0.727) or overall survival (P= 0.218). Five-
year survival rates were 69.7% in the sequentially operated group, 65.1% in the liver group, and 50.0% in the
lung group.
Conclusion: Long-term outcomes after sequential liver and lung resections of CRC metastases were comparable to
outcomes after isolated liver or lung metastasectomies. Therefore, aggressive surgical interventions should be
considered for patients with both liver and lung metastases of CRC.
1. Introduction
Colorectal carcinoma (CRC) is the third most common cancer
worldwide, and the most common metastatic sites are liver and lungs
[1,2]. Approximately half of the patients with CRC develop liver me-
tastases [1,3] and 8–20% develops lung metastases [4–6]. Recent stu-
dies have shown that surgical resection is the most efficient treatment
of isolated liver or lung metastasis. After liver resections, the 5-year
survival rates were up to 58% [7–10] and 10-year survival rates were
up to 25–28% [9,11]. After lung resections, the 5-year survival rates
were 36–45% [1,10,12–14].
Previously, colorectal cancer metastasis to both liver and lungs was
considered disseminated disease, and therefore, inoperable. Several
recent patient series studies have reported improved survival after se-
quential resections of liver and lung metastases; the 5-year survival
rates ranged from 30 to 70% [1,2,4,10,12,13,15–19]. Modern
chemotherapy, and possibly biological agents, have played a major role
in improving long-term outcomes after sequential liver and lung re-
sections [1]. However, the reported survival rates vary considerably,
and surgical treatment of patients with CRC liver and lung metastases
has been challenged, due to controversial outcomes [16,20,21]. Dif-
ferent studies are difficult to compare, due to the differences in study
plans, outcome measurements (e.g., starting from the first or last me-
tastasectomy), and selection biases.
The present study aimed to compare matched patient groups with
CRC metastases. In the first group, patients had both liver and lung
metastases and underwent sequential liver and lung resections. In the
second group, patients had isolated liver metastases and underwent
liver resection(s). In the third group, patients had isolated lung me-
tastases and underwent lung resection(s). We compared differences in
overall survival (OS, primary endpoint) and disease-free survival (DFS,
secondary endpoint) between these three groups.
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2. Materials and methods
2.1. Materials and methods
All patients underwent lung and/or liver metastasectomies of col-
orectal carcinoma metastases with a curative intent at Helsinki
University Hospital between July 2002 and September 2015. In the
present study, all data were retrospectively collected and analyzed to
define long-term outcomes.
Three groups were compared: the sequentially operated group
consisted of patients (n=33) that underwent both liver and lung me-
tastasectomies. In this group, metastases in liver and lung were diag-
nosed synchronously or sequentially. Two control groups comprised:
the liver group consisted of patients with isolated, resectable liver
metastases (n=38); and the lung group consisted of patients with
isolated, resectable lung metastases (n= 34). For the control groups,
patients were selected as near as possible to the same time period, to
correspond patients in the sequentially operated group. Control and
study group patients were also matched for the age. All patients re-
ceived neoadjuvant and/or adjuvant chemotherapy. Twenty-two pa-
tients underwent re-resections, due to recurrent metastases, and these
operations were included in the analyses.
The following demographic data were collected: age and sex; loca-
tion of primary tumor (colon/rectum); nodal involvement, and metas-
tasis classification system (pTNM-staging); synchronous versus meta-
chronous metastases; and mutation status (KRAS, BRAF), when
available. The number and sizes of metastases and tumor characteristics
were also collected based on the pathological analyses and analyzed.
For the liver metastases, vascular, neural, and biliary invasions were
evaluated by experienced histopathologists.
Metastases were considered synchronous when diagnosed within 6
months after the primary colorectal cancer diagnosis.
Decisions on the surgical and oncological treatments were made by
the multidisciplinary team (MDT).
Resectability of liver metastases was determined in MDT. Resection
should achieve negative resection margins while preserving future liver
remnant at least 30% of the total estimated liver volume and sparing at
least two segments and maintaining vascular inflow and outflow and
biliary drainage.
Lung metastases were considered resectable if R0 resection was
possible without pulmonectomy and patients had no extrathoracic
disease. Bilateral metastases were not contraindication. If synchronous
liver and lung metastases, liver was operated at the first.
DFS was defined as the time interval between the last metasta-
sectomy and recurrence, death or last follow-up. OS was defined as the
time interval from the first metastasectomy to the date of death or last
follow-up.
2.2. Statistics
Data were analyzed with IBM SPSS software version 22.0 (United
States). Demographics and histopathological details were compared
between groups with the Chi-square test, Fisher's test, One-Way
ANOVA, or Kruskal Wallis' test, as appropriate. DFS and OS were ana-
lyzed with the Kaplan-Meier estimation method. Survival rates were
compared between groups with the log-rank test. P-values less than
0.05 were considered significant.
3. Results
A total of 105 patients were included in this study. Demographic
data are presented in Table 1. The median follow-up times were 67.1
months (range:7.1–163.0) for all patients; 65.8 months (range
14.9–162.8) for the sequentially operated group; 81.6 months (range
7.1–163.0) for the liver group; and 56.4 months (range 10.8–138.8,
n.s.) for the lung group. Twenty-two patients received multiple
operations.
3.1. The primary tumor
The primary tumor locations were significantly different between
the three groups. Primary tumors in the rectum were observed in the
majority of patients (79.4%) with lung metastases, but in less than half
(39.5%) of the liver resection group, and in 57.6% of the sequentially
operated group (p=0.003) (Table 1). Metastases were synchronous
Table 1
Demographics of the three groups of patients that underwent surgery for col-
orectal cancer metastases.
Characteristic Group 1
Resected liver
and lung
metastases,
n= 33
Group 2
Resected liver
metastases,
n= 38
Group 3
Resected lung
metastases,
n= 34
p-value
Age, years
(median,
range)
65.0 (36–80) 60.0 (32–82) 61.0 (38–78) 0.677
Gender 0.362
male 20 (60.6%) 24 (63.2%) 16 (47.1%)
female 13 (39.4%) 14 (36.8%) 18 (52.9%)
Primary tumor 0.003
rectum 19 (57.6%) 15 (39.5%) 27 (79.4%)
colon 14 (42.4%) 23 (60.5%) 7 (20.6%)
T1-2 4 (12.5%) 5 (15.6%) 5 (14.3%) 0.999
T3-4 28 (87.5%) 30 (85.7%) 27 (84.4%)
Node status 0.285
N0 10 (31.3%) 18 (51.4%) 15 (45.5%)
N1 11 (34.4%) 12 (34.3%) 12 (36.4%)
N2 11 (34.4%) 5 (14.3%) 6 (18.2%)
Synchronous 0.008
yes 24 (72.7%) 19 (50.0%) 12 (35.3%)
no 9 (27.3%) 19 (50.0%) 22 (64.7%)
KRAS 0.021
Wild type 17 (65.4%) 11 (73.3%) 7 (31.8%)
Mutation 9 (34.6%) 4 (26.7%)a 15 (68.2%)b
Values are the number of patients (%), unless otherwise indicated. aCompared
to group 1: P= 0.734; bCompared to group 1: P= 0.041; KRAS: Kirsten rat
sarcoma virus oncogene involved in regulating cell division.
Table 2
Comparison of histological characteristics of liver metastases between patients
with A. combined metastases and B. patients with only liver metastases.
Characteristic A. Patients (n= 33) with
total of 40 liver resections
B. Patients (n= 38) with
total of 50 liver resections
p-value
Number of metastases 0.999
≤ 2 29 (74.4%) 38 (76.0%)
> 2 10 (25.6%) 12 (24.0%)
Size of the largest metastases 0.824
≤ 30mm 24 (61.5%) 33 (66.0%)
> 30mm 15 (38.5%) 17 (34.0%)
Vitality 0.359
< 50% 16 (44.4%) 15 (32.6%)
≥ 50% 20 (55.6%) 31 (67.4%)
Invasiona 0.259
yes 0 3 (6.1%)
no 36 (100.0%) 46 (93.9%)
Extent of resections 0.382
minor 20 (52.6%) 32 (64.0%)
major 18 (47.4%) 18 (36.0%)
Residual tumor 0.289
R0 36 (94.7%) 43 (86.0%)
R1 2 (5.3%) 7 (14.0%)
Complicationsb 0.999
yes 3 (7.5%) 4 (8.2%)
no 37 (92.5%) 45 (91.8%)
a Biliary, nervous, and/or vascular invasion.
b Pulmonary embolism, deep vein thrombosis, pneumonia and/or biloma.
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with the primary tumor in 72.7% of the sequentially operated group,
50.0% of the liver group, and 35.3% of the lung group (p=0.008).
3.2. Tumor stages
Tumor stages are shown in Table 1. T-stage or the node status of the
primary tumor were not significantly different between the three
groups (p= 0,999 and p=0.285, respectively). Most patients had T3-
stage disease, including 71.3% of the sequentially operated group,
65.7% of the liver group, and 78.1% of the lung group. The N0-stage
was found in 31.3% of the sequentially operated group, 51.4% of the
liver group, and 45.5% of the lung group.
3.3. Mutation status
The results of mutation analyses are shown in Table 1. The patients
were not consistently tested for KRAS mutations. The prevalence of the
KRAS mutation was significantly higher in the lung group (68.2%) than
in the sequentially operated group (34.6%) and the liver group (26.7%;
p=0.021). Only one patient had BRAF mutation among the tested
patient. This patient had liver and lung metastases and is now alive and
recurrence-free.
3.4. Histopathology
Histopathological findings on the resected liver and lung metastases
are shown in Tables 2 and 3, respectively. We found no significant
differences in any histological characteristics.
3.5. Complications
The rate of complications was similar between the sequentially
operated and liver groups (Table 2). The most common complications
Table 3
Comparison of histological characteristics of lung metastases between A. pa-
tients with combined metastases and B. patients with only lung metastases.
Characteristic A.Patients (n= 33) with
total of 49 lung
resections
B. Patients (n=34)
with total of 53 lung
resections
p-value
Site of lung metastases 0.309
right 27 (55.1%) 24 (45.3%)
left 16 (32.7%) 25 (47.2%)
both 6 (12.2%) 4 (7.5%)
Resection type 0.523
wedge 32 (65.3%) 29 (54.7%)
segmentectomy 11 (22.4%) 14 (26.4%)
lobectomy 6 (12.2%) 10 (18.9%)
Surgical techniques 0.207
thoracotomy 16 (32.7%) 26 (49.1%)
VATS 30 (61.2%) 26 (49.1%)
both 3 (6.1%) 1 (1.9%)
Number of metastases 0.828
1 33 (70.2%) 34 (66.7%)
≥ 2 14 (29.8%) 17 (33.3%)
Size of the largest metastasis 0.213
≤ 15mm 31 (67.4%) 27 (52.9%)
>15mm 15 (32.6%) 24 (47.1%)
Complicationsa 0.424
yes 4 (8.2%) 2 (3.8%)
no 45 (91.8%) 51 (96.2%)
a Complications: pneumonia, empyema, deep vein thrombosis; VATS: Video-
assisted thoracoscopic surgery.
Figure 1. Overall survival.
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were pulmonary embolism, deep vein thrombosis, and pneumonia. One
patient developed a postoperative biloma.
The sequentially operated and lung metastases groups also had si-
milar rates of complications (Table 3). The most common complications
were pneumonia, empyema, and deep vein thrombosis.
3.6. Time intervals between metastasectomies
The median time intervals between the first and second metasta-
sectomies were 15.4 months (range: 1.2–67.4) for the sequentially op-
erated group (n=33), 14.5 months (range: 1.9–69.7) for the liver
group (n=38), and 4.9 months (range: 0.7–35.5) the lung group
(n=34). The time intervals between the second and third metasta-
sectomies were 14.5 months (range: 3.7–31.2) for the sequentially op-
erated group (n=33), 19.7 months (range: 8.9–63.5) for the liver
group (n=38), and 6.5 months (range: 2.6–17.2) for the lung group
(n=34).
3.7. Overall and disease-free survival rates
The OS was evaluated starting from the first metastasectomy. The
DFS was evaluated starting from the last metastasectomy. The median
OS rates were 133.0 months in the sequentially operated group, 100.0
months in the liver group, and 49.0 months in the lung group (Fig. 1).
The median DFS rates were 18.0 months in the sequentially operated
group, 26.0 months in the liver group, and 11.0 months in the lung
group (Fig. 2). The three groups were not significantly different in ei-
ther DFS (p=0.727) or OS (p= 0.218).
The 1-, 3-, and 5-year OS rates were 100.0%, 84.4%, and 69.7%,
respectively, in the sequentially operated group; 94.7%, 81.4%, and
65.1%, respectively, in the liver group; and 94.1%, 61.8%, and 50.0%,
respectively, in the lung group: (n.s).
4. Discussion
Surgical resection of isolated liver or lung metastasis is the standard
treatment in metastatic colorectal carcinoma, but the long-term out-
come of patients that require resections of both liver and lung metas-
tases had not been established. In the present study, we analyzed long-
term survival of patients that underwent sequential liver and lung re-
sections compared to patients that underwent either isolated liver or
isolated lung resections.
We found that the 5-year OS was 69.7% for patients in the se-
quentially operated group. In previous studies, 5-year OS rates were
reported to be 40.7–77.5% [2,10,12,15,18,19,22–24]. The variation in
reported survival rates was partly due to different starting times for the
calculations. OS times were counted starting from the last metasta-
sectomy in Brouquet et al. [2], from the liver resection in Andres et al.
[18], and from the resection of the primary tumor in Limmer et al. [15].
Only Marudanayagam et al. [12] counted OS times from the first me-
tastasectomy, which was the method used in the present study. The
higher OS in the present study was most likely due to strict patient
selection. Marin et al. [10] found that patient selection significantly
affected the survival results [10]. In some earlier studies, historical
controls were used for comparisons [1,10,16], or there was no control
group at all [1,4,12]. On systematic review and meta-analysis of Gon-
zalez et al. [25] previously resected liver metastases did not effect on
OS rates with patients who underwent lung metastasectomy.
Surprisingly, in the present study, survival rates did not differ
among the three groups. Marudanayagam et al. [12] and Andres et al.
[18] compared survival after sequential liver and lung resections to
survival after isolated liver resections. They reported similar survival
Fig. 2. Disease-free Survival counted from the last metastasectomy.
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rates between these groups. Brouquet et al. [2], reported that patients
with colorectal cancer metastases showed better survival rates after
sequential liver and lung resections (50% survived for 5 years), com-
pared to survival after isolated liver resections (40% survived for 5
years). However, those results might have been slightly biased, because
the control group consisted of a large, unselected population of patients
that underwent liver resections over a long time period.
Hattori et al. [13] found that OS after an isolated pulmonary me-
tastasectomy was significantly better than after sequential liver and
lung metastasectomies, although the DFS was similar. Landes at al [16]
reported that, a prior liver resection was an adverse prognostic factor
for survival after a pulmonary metastasectomy compared to survival
without a prior liver resection.
In the present study, recurrence rates were quite similar between
the three groups; the 5-year DFS varied between 31 and 41%. Brouquet
et al. [2] reported 25% DFS for patients with sequential liver and lung
resections, and Andres et al. [18] found 5-year DFS in 31.0% of patients
with liver resections and only 12.9% of patients with both liver and
lung resections. Differences between studies might have been due to a
selection bias.
The KRAS mutation rate was highest in patients with lung resec-
tions, perhaps reflecting the slightly, but not significantly, lower sur-
vival rate in the lung group compared to the other two groups. KRAS
mutations were reported to be associated with worse DFS and OS rates
[26,27].
Our finding that patients with lung resections had the highest pro-
portion of rectal primary tumors was noted in earlier studies [28]. At
least partly, this association might be due to the venous drainage from
the distal rectum to the vena cava inferior; and also due to differences
in molecular patterns between rectal and colonic cancers [29].
The high rate of synchronous metastases in the sequentially oper-
ated group might be a result of selection bias, because multiple me-
tastasis sites indicate more aggressive disease. However, synchronicity
did not affect survival rates in this study. All treatment decisions were
evaluated by a multidisciplinary team and were based on the re-
commendations published in a recent consensus statement [30].
The limitations of the present study included relatively small
number of patients in each group and its retrospective nature. We in-
tended to minimize selection bias by matching the patients in each
group within the same time period. Patients in the liver group were
better matched to the study group, because there were more patients in
the liver group. The groups differed significantly in the KRAS mutation
status, primary tumor location, and synchronous vs. metachronous
presentation.
In conclusion, we showed that, in patients with concomitant liver
and lung metastases of colorectal cancer origin, a curative surgical
approach gave a good long-term outcome, comparable to those
achieved with isolated liver and lung resections. Thus, combined me-
tastases in liver and lung should not contraindicate resection.
Treatment options should be based on the resectability of the metas-
tases and a history of appropriate chemotherapy.
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